Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2010
The purpose of the study is to investigate the long-term safety and the antiviral activity of the optimal doses of LB80380 for additional 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to entecavir 0.5 mg.
Epistemonikos ID: 5ec5dece2a72ec8036affe895c2d51f3b5795cc4
First added on: Nov 24, 2021